Condition
Major Adverse Cardiovascular Events (MACE)
Total Trials
4
Recruiting
1
Active
2
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
2Total
Not Applicable (2)
Trial Status
Active Not Recruiting1
Recruiting1
Not Yet Recruiting1
Completed1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT06843005Not ApplicableRecruitingPrimary
Serial Coronary CTA-based Plaque Progression Detection for Management of Coronary Heart Disease
NCT07431515Completed
Long-term Risk of Cardiovascular Disease in Living Kidney Donors
NCT06832371Active Not Recruiting
Evaluation of the Effect of Lomitapide Treatment on Major Adverse Cardiovascular Events (MACE) in Patients With Homozygous Familial Hypercholesterolemia
NCT07348328Not ApplicableNot Yet Recruiting
Vitamin B Supplementation for Patients Undergoing Cardiovascular Surgery
Showing all 4 trials